Genmab Stock - New employee RSUs and warrants while sector re-rates

Edited by ad hoc news Sector & Peer-Group Desk. Verified prior to publication on 06/19/2026, 13:25 CET. Details in the imprint.

Genmab (DK0010272202) has refreshed its long-term incentive plans with new restricted stock units and warrants for staff. The move comes as the oncology-focused biotech navigates a mixed week for European drug developers, with investors reassessing growth and valuation across the sector.

Fresh RSUs and warrants granted

On 06/11/2026, Genmab announced that its board had granted 15,894 restricted stock units and 15,494 warrants to employees under the company’s long-term incentive plans. The grants were detailed in a company announcement distributed via GlobeNewswire and Via Ritzau. Company announcement on grant of RSUs and warrants

The warrants each entitle the holder to subscribe for one Genmab share at a predefined exercise price, while the restricted stock units convert into shares subject to vesting conditions. The company said the awards are designed to support retention and align employee incentives with long-term shareholder value.

Weekly review and peer comparison

Over the past week, Genmab shares on Nasdaq Copenhagen have traded in the low DKK 220s, modestly below levels seen earlier in June. A German trading venue quote shows bid and ask around DKK 220.80 and DKK 222.70 equivalent in euro terms, underlining a relatively tight range. German quote overview for Genmab

Against a backdrop of softer sentiment toward European biotechs, Genmab’s recent performance has been broadly in line with peers such as MorphoSys and BioNTech, which have also seen muted moves as investors digest trial updates and valuation resets in the sector.

How Genmab compares in biotech

In terms of scale, Genmab sits in the mid-to-large-cap bracket among European drug developers, smaller than giants like Novo Nordisk but larger than many early-stage biotechs. Its market capitalization in Copenhagen runs into the tens of billions of Danish kroner, anchoring it as a key regional oncology name.

Unlike diversified pharma groups, Genmab relies heavily on oncology antibodies and partnered programs for its revenue base. That profile makes the stock more sensitive to clinical news, regulatory milestones and partner decisions than to broad macroeconomic indicators, a pattern mirrored across its immediate biotech peer group.

Analyst sentiment and sector tone

Analyst research remains broadly constructive. Deutsche Bank recently adjusted its price target on Genmab to DKK 2,250 from DKK 2,400 while reiterating a Buy rating, signaling continued confidence despite near-term volatility. Summary of Deutsche Bank target adjustment

Net-net, the tone on the broader European biotech sector is cautious but not fundamentally negative. Investors are rewarding clear clinical progress and disciplined capital allocation, while being more critical of pipelines with binary risk and limited diversification.

The product behind the stock

Genmab builds its business around antibody-based cancer therapies, most prominently the anti-CD38 antibody daratumumab, marketed by Johnson & Johnson under the brand Darzalex for multiple myeloma and related blood cancers. The company also advances bispecific antibody candidates such as epcoritamab in collaboration with partners.

Where the stock trades today

The shares of Genmab (DK0010272202) trade on Nasdaq Copenhagen at DKK 1,620.00 as of 06/19/2026, 13:25 CET.

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.